Latest studies
- RecruitingPHASE3
A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
This study is testing a new medicine, Etavopivat, for sickle cell disease and thalassaemia. It looks at how safe and effective the treatment is over a long period for people already benefiting from it in previous studies. The goal is to improve oxygen delivery in the body.
Sickle Cell DiseaseThalassemiaKenya - RecruitingPHASE2
A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
This study is looking at a new once-a-day medicine called etavopivat for young people with sickle cell disease. We want to see how safe it is, how long it stays in the body, and if it helps improve their health.
Sickle Cell DiseaseKenya - RecruitingPHASE3
Low INR to Minimize Bleeding With Mechanical Valves Trial
This study is looking at whether taking a lower dose of a blood thinner called warfarin is safer for people with a mechanical heart valve in their main artery. We want to see if this lower dose can prevent serious bleeding without increasing the risk of blood clots or stroke.
Bleeding Post-mechanical Valve ReplacementThromboembolism Post-mechanical Valve ReplacementKenya - RecruitingPHASE3
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
This study looks at a new medicine called etavopivat for people with sickle cell disease. It aims to see if it reduces painful crises, organ damage, and tiredness, and improves exercise. Participants will get either the medicine or a dummy pill.
Sickle Cell DiseaseKenya - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
This study compares a new drug, Giredestrant, with standard hormone therapy for early breast cancer. It's for people with a specific type of breast cancer (ER-positive, HER2-negative) who have already had surgery.
Early Breast CancerKenya - Active not recruitingPHASE3
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
This study looks at the long-term safety of a treatment called astegolimab for people with a lung condition called COPD. It's for people who have already taken part in previous studies of this drug.
Chronic Obstructive Pulmonary DiseaseKenya - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
This study looks at a new drug, Giredestrant, combined with an existing treatment called Phesgo, for advanced breast cancer. It aims to see if this new combination is safe and works better than Phesgo alone for people with specific types of breast cancer.
Locally Advanced or Metastatic Breast CancerKenya - RecruitingNA
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
This study looks at a new, shorter radiation treatment for women whose breast cancer has come back, or who have developed a new cancer in the same breast after earlier treatment. It aims to see if this quicker, one-week course of radiation is safe and works well.
Breast CancerBreast Cancer RecurrentKenya - RecruitingPHASE3
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
This study is testing a new monthly tablet, MK-8527, to see if it can prevent HIV as effectively as current daily medicine. Researchers want to check its safety and how well people tolerate it, hoping to offer a convenient new way to protect against HIV.
Human Immunodeficiency Virus (HIV)HIV Pre-Exposure ProphylaxisKenya - RecruitingPHASE3
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
This study is testing a new drug, giredestrant, against a standard treatment for advanced breast cancer. It's for people whose cancer has grown resistant to previous hormone therapy, to see if giredestrant, combined with other drugs, works better and is safe.
Estrogen Receptor-Positive, HER2-Negative Advanced Breast CancerKenya - Active not recruitingPHASE3
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
This study is looking at new ways to treat advanced liver cancer that can't be removed by surgery. It combines existing medications with a new one to see if this mix works better and is safe. The aim is to find improved first-line treatments for this type of cancer.
Hepatocellular CarcinomaKenya - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
This study is looking at a new combination of treatments, Inavolisib and Phesgo, for HER2-positive breast cancer that has spread. We want to see if this new combination works better and is safe compared to Phesgo alone after initial treatment.
Metastatic Breast CancerKenya - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
This study is looking at a new medicine called fenebrutinib for people with relapsing multiple sclerosis (RMS). It wants to see if fenebrutinib is safe and works better than an existing medicine, teriflunomide, at slowing down the disease and reducing flare-ups.
Relapsing Multiple SclerosisKenya - Active not recruitingPHASE1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
This study is testing a new medicine, GDC-6036, for people with advanced cancers that have a specific genetic change called KRAS G12C. It will look at how safe the medicine is and if it helps shrink tumors, sometimes combined with other treatments.
Non-Small Cell Lung CancerColorectal CancerAdvanced Solid TumorsKenya - Recruiting
Hospitalised COVID-19 Patients Cohort Study in the EuCARE Project
This study looks at hospitalised COVID-19 patients across the world. Researchers want to understand how different types of the virus and vaccination affect how ill people get and how they recover. They're collecting patient information and some blood samples to learn more.
COVID-19Kenya - Recruiting
Exploring the hidden burden of living with Glanzmann thrombasthenia
This study wants to hear from people living with Glanzmann thrombasthenia (GT) and their caregivers. We want to understand the daily challenges and feelings of those affected. Your stories can help improve support and understanding for everyone with GT.
Glanzmann thrombastheniaKenya - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
This study looked at new treatments for HER2-positive breast cancer that had already been treated but still showed signs of cancer after surgery. Researchers wanted to see if adding certain drugs could prevent the cancer from coming back.
Breast CancerKenya - RecruitingPHASE2, PHASE3
A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
This study is looking at a new medicine called osivelotor for people with sickle cell disease. It aims to see if it's safe, how well it works, and what dose is best. Both adults and teenagers can take part.
Sickle Cell DiseaseKenya - Recruiting
BPH Global Registry
This study is gathering information on men who are treated for an enlarged prostate (BPH) and related bladder symptoms. We want to understand what treatments are being used globally and how successful they are, to help improve care in the future.
Benign Prostatic HyperplasiaLower Urinary Tract SymptomsKenya - Active not recruitingPHASE2, PHASE3
A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)
This study is looking at a new medicine called mitapivat for sickle cell disease. It aims to find the right dose and see if it helps increase healthy red blood cells and reduce painful crises.
Sickle Cell DiseaseKenya - Active not recruitingPHASE3
A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo
This study looks at a new treatment for vitiligo, a condition where patches of skin lose their colour. It compares a special implant (afamelanotide) combined with light therapy (NB-UVB) against light therapy alone, to see how well they work and if they are safe.
VitiligoKenya - Active not recruitingPHASE3
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
This study looks at a new drug, astegolimab, for people with COPD who have flare-ups often. It compares the new drug to a dummy treatment (placebo) to see if it's safe and helps improve their breathing and reduce flare-ups.
Chronic Obstructive Pulmonary Disease (COPD)Kenya - Recruiting
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
This study, called IRONMAN, is collecting information from men with advanced prostate cancer across many countries, including the UK. It aims to understand treatments, how they vary, and what helps men live longer and have a better quality of life.
Prostate CancerKenya - Active not recruitingPHASE3
A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
This study is testing a new tablet medicine called etavopivat for people aged 12 to 65 with sickle cell disease. It aims to see if the medicine can improve a patient's red blood cells and reduce painful sickle cell crises. Half the group will receive the new treatment, the other a placebo.
Sickle Cell DiseaseKenya - Active not recruitingPHASE3
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
This study looks at new treatments for a type of oesophageal cancer that hasn't spread after initial therapy. It tests two new medicines, tiragolumab and atezolizumab, to see if they can help stop the cancer from coming back or getting worse.
Esophageal Squamous Cell CarcinomaKenya - Active not recruitingPHASE3
DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)
This study is testing a new combination medicine, DOR/ISL, for people newly diagnosed with HIV-1 who haven't started treatment yet. It compares this new medicine to an existing treatment to see if it's as good at reducing the amount of HIV in the body.
HIV-1 InfectionKenya